AZ’s Pangalos: what the pharma brings to COVID-19 fight, and where it turns to others

In a conversation with BioCentury, AstraZeneca’s Menelas Pangalos highlighted the technologies the pharma thinks could be difference-makers in the pandemic, and the external resources required to reduce them to practice.

In the past month, AstraZeneca plc (LSE:AZN; NYSE:AZN) has announced it is developing mAbs against COVID-19 and helping expand the U.K.’s diagnostic testing capacity. It will also reposition assets to treat patients with severe disease, though it has not yet disclosed candidates (see “U.K. Biopharma COVID-19 Fight”)...